Form 8-K - Current report:
SEC Accession No. 0001193125-23-021612
Filing Date
2023-02-01
Accepted
2023-02-01 16:29:34
Documents
12
Period of Report
2023-01-30
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d455024d8k.htm   iXBRL 8-K 29088
  Complete submission text file 0001193125-23-021612.txt   152830

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA spro-20230130.xsd EX-101.SCH 2876
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE spro-20230130_lab.xml EX-101.LAB 17993
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE spro-20230130_pre.xml EX-101.PRE 11278
6 EXTRACTED XBRL INSTANCE DOCUMENT d455024d8k_htm.xml XML 3351
Mailing Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139
Business Address 675 MASSACHUSETTS AVENUE 14TH FLOOR CAMBRIDGE MA 02139 857-242-1600
Spero Therapeutics, Inc. (Filer) CIK: 0001701108 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38266 | Film No.: 23577183
SIC: 2834 Pharmaceutical Preparations